Alzheimer’s disease (AD) drug development is the ultimate high-stakes gamble in biopharma. For decades, it was known as the “graveyard” of promising molecules, defined by
The traditional boundaries between metabolic health and psychiatric care are dissolving. At Salience Clinical, we view the brain not in isolation, but as the most
The Future of Biologics and Cell-Based Therapies in Neurodegenerative and Neuropsychiatric Disease Treatment Prepared by Salience Clinical, LLC Independent analysis at the intersection of clinical
